Literature DB >> 22510004

Advances in ocular drug delivery.

Mutasem Rawas-Qalaji1, Cheryl-Ann Williams.   

Abstract

Eye drops have long been the primary ocular drug delivery dosage form used to treat ocular disorders ranging from superficial conditions to intravitreal diseases. The ocular anatomical structure and physiological protective mechanisms are one of the most formidable barriers to drug penetration that have significantly reduced the drug's efficacy and target selectivity while sometimes causing ocular tissue damage. There are many new and innovative advances in ocular drug delivery due to better understanding of the structure and function of the eye, the nature of its diseases, and how to overcome or utilize its protective barrier(s), which resulted in increased bioavailability and longer duration of action of the administered drugs, therefore, more effective disease management. We seek in this article to present a comprehensive overview of the basic required knowledge about the barriers for drug delivery to the eye and the major breakthroughs and advances in ocular drug delivery to the anterior, posterior and intravitreal segments of the eye.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22510004     DOI: 10.3109/02713683.2011.652286

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  22 in total

1.  Curcumin nanoparticles inhibit corneal neovascularization.

Authors:  Nirparaj Pradhan; Rajdeep Guha; Sushovan Chowdhury; Sudip Nandi; Aditya Konar; Sarbani Hazra
Journal:  J Mol Med (Berl)       Date:  2015-04-17       Impact factor: 4.599

Review 2.  Nanotechnology in corneal neovascularization therapy--a review.

Authors:  Lilian Gonzalez; Raymond J Loza; Kyu-Yeon Han; Suhair Sunoqrot; Christy Cunningham; Patryk Purta; James Drake; Sandeep Jain; Seungpyo Hong; Jin-Hong Chang
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-20       Impact factor: 2.671

3.  G-quartet oligonucleotide mediated delivery of proteins into photoreceptors and retinal pigment epithelium via intravitreal injection.

Authors:  Derek Leaderer; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Exp Eye Res       Date:  2016-02-27       Impact factor: 3.467

4.  A flexible device for ocular iontophoretic drug delivery.

Authors:  Yushi Zhang; Yao Chen; Xiaoxue Yu; Yangjia Qi; Yufeng Chen; Yuxi Liu; Yuntao Hu; Zhihong Li
Journal:  Biomicrofluidics       Date:  2016-02-24       Impact factor: 2.800

Review 5.  Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.

Authors:  Olivia L Lanier; Miranda G Manfre; Claire Bailey; Zhen Liu; Zachary Sparks; Sandesh Kulkarni; Anuj Chauhan
Journal:  AAPS PharmSciTech       Date:  2021-03-14       Impact factor: 3.246

6.  Sunitinib malate-loaded biodegradable microspheres for the prevention of corneal neovascularization in rats.

Authors:  Jin Yang; Lixia Luo; Yumin Oh; Tuo Meng; Guihong Chai; Shiyu Xia; David Emmert; Bing Wang; Charles G Eberhart; Seulki Lee; Walter J Stark; Laura M Ensign; Justin Hanes; Qingguo Xu
Journal:  J Control Release       Date:  2020-08-18       Impact factor: 9.776

7.  Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery.

Authors:  Maziar Mohammadi; Kisha Patel; Seyedeh P Alaie; Ron B Shmueli; Cagri G Besirli; Ronald G Larson; Jordan J Green
Journal:  Acta Biomater       Date:  2018-04-21       Impact factor: 8.947

8.  In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device.

Authors:  Kevin D Lance; Daniel A Bernards; Natalie A Ciaccio; Samuel D Good; Thaís S Mendes; Max Kudisch; Elliot Chan; Mynna Ishikiriyama; Robert B Bhisitkul; Tejal A Desai
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

Review 9.  Ocular delivery of macromolecules.

Authors:  Yoo Chun Kim; Bryce Chiang; Xianggen Wu; Mark R Prausnitz
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

10.  Efficacy of Antibody Delivery to the Retina and Optic Nerve by Topical Administration.

Authors:  Stacy Hu; Steven Koevary
Journal:  J Ocul Pharmacol Ther       Date:  2016-01-15       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.